GKOS - Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst | Benzinga
Shares of Glaukos Corp (NYSE: GKOS) continued to climb in early trading on Thursday, after the company’s iDose TR (travoprost intracameral implant) received U.S. Food and Drug Administration (FDA) approval for glaucoma patients.
The Glaukos Analyst: JPMorgan Chase's Allen Gong upgraded the rating for Glaukos from Neutral to Overweight, while raising the price target from $66 to $91.
Gong also cited iDose as the "biggest driver to watch,” with more benefits coming in the back half of 2024 and significant upside to numbers in 2025 and beyond.
Check out ...